weight regain after stopping semaglutide trial The returns. Here's what your prescriber may not have told you. The STEP 1 extension found that patients regained approximately two-thirds of their lost weight within one year of GLP-1 drugs work while you're

ACE/ARB, angiotensin converting enzyme inhibitors/angiotensin-receptor blockers Postop, Postprocedural

For prescribers, this compounded formulation offers the flexibility to adjust dosages based on patient response and specific clinical requirements, which is often not possible with commercially available products

Lilly, which also has significant exposure to the weight-loss drug market, saw its stock come under pressure as well

Bearish Takeaways Mizuho also flags concentration risk, noting that the investment case is still tightly linked to the weight loss management program, which could leave the story sensitive to any changes in GLP-1 adoption or competitive dynamics